ABBVIE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT06389136
- Locations
- 🇺🇸
Beacon Clinical Research /ID# 263843, Quincy, Massachusetts, United States
🇺🇸Great Lakes Research Group - Bay City /ID# 263535, Bay City, Michigan, United States
🇺🇸Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas, United States
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06387394
- Locations
- 🇺🇸
Skin Care and Laser Physicians of Beverly Hills /ID# 248223, Los Angeles, California, United States
🇺🇸Skin Laser and Surgery Specialists of NY and NJ /ID# 251501, Hackensack, New Jersey, United States
🇺🇸Dallas Plastic Surgery Institute /ID# 248220, Dallas, Texas, United States
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06365853
- Locations
- 🇺🇸
New York Oncology Hematology - Albany Cancer Center /ID# 269345, Albany, New York, United States
🇺🇸Women'S Cancer Care Associates /ID# 269980, Albany, New York, United States
🇺🇸Norton Healthcare /ID# 269070, Louisville, Kentucky, United States
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
- Conditions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06362031
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
- Conditions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 89
- Registration Number
- NCT06362044
- Locations
- 🇯🇵
National Cancer Center Hospital East /ID# 265970, Kashiwa, Chiba, Japan
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 10
- Registration Number
- NCT06346288
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill /ID# 263316, Chapel Hill, North Carolina, United States
🇮🇱Shaare Zedek Medical Center /ID# 262738, Jerusalem, Yerushalayim, Israel
🇺🇸UTHealth Women's Research Program - Memorial City /ID# 263939, Houston, Texas, United States
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2800
- Registration Number
- NCT06345339
- Locations
- 🇺🇸
Scripps Whittier Diabetes Institute /ID# 259215, La Jolla, California, United States
🇺🇸Facey Medical Foundation /ID# 260863, Mission Hills, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian /ID# 260990, Newport Beach, California, United States
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 336
- Registration Number
- NCT06333860
- Locations
- 🇨🇦
Private Practice - Dr. Angelique Gagne-Henley /ID# 264267, St-Jérôme, Quebec, Canada
🇩🇪Universitaetsklinikum Freiburg /ID# 263069, Freiburg, Baden-Wuerttemberg, Germany
🇩🇪Beldio Research GmbH /ID# 263073, Memmingen, Bayern, Germany
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06332534
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio /ID# 262712, Sevilla, Spain
🇺🇸OSF St. Francis Medical Center /ID# 262192, Peoria, Illinois, United States
🇺🇸Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis, Indiana, United States
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06318273
- Locations
- 🇺🇸
University of Chicago Medical Center /ID# 261605, Chicago, Illinois, United States
🇦🇺Chris O'Brien Lifehouse /ID# 261731, Camperdown, New South Wales, Australia
🇺🇸City of Hope /ID# 262059, Duarte, California, United States